Plasmacytoid (CD68+CD123+) monocytes may play a crucial role in the pathogenesis of hydroa vacciniforme: A case report

American Journal of Dermatopathology

Volumn 31, Issue 8, 2009, Pages 828-833

  Varughese, Neal ^a   Petrella, Tony ^b   Singer, Mitchel ^a   Carlson, J Andrew ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Centre de Pathologie   (France)

Author keywords

Apoptosis; Epstein Barr virus; Interferon type 1; Latent viral infection; Photodermatosis; Plasmacytoid monocytes; Smallpox

Indexed keywords

CD123 ANTIGEN; CHLORDANE;

ADOLESCENT; ANAMNESIS; ARTICLE; CASE REPORT; CELL INFILTRATION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; HYDROA VACCINIFORME; MONOCYTE; PATHOGENESIS; PHENOTYPE; PLASMACYTOID MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY;

ADOLESCENT; ANTIGENS, CD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; HYDROA VACCINIFORME; IMMUNOPHENOTYPING; MONOCYTES;

EID: 74349089068     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181a8527f     Document Type: Article

References (44)

1. Bazin E. Lecxons Théoriques et Cliniques sur les Affections Génériques de la Place. Paris, France: Delahaye; 1862.
2. Gupta G, Man I, Kemmett D. Hydroa vacciniforme: a clinical and followup study of 17 cases. J Am Acad Dermatol. 2000;42:208-213.
3. Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol. 2006;142:587-595.
4. Morizane S, Suzuki D, Tsuji K, et al. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br J Dermatol. 2005; 153:981-986.
5. Iwatsuki K, Ohtsuka M, Akiba H, et al. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol. 1999;40:283-284.
6. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol. 2009;129:302-308.
7. Facchetti F, Vermi W, Mason D, et al. The plasmacytoid monocyte/ interferon producing cells. Virchows Arch. 2003;443:703-717.
8. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008;19:3-19.
9. Regan TD, Norton SA. The scarring mechanism of smallpox. J Am Acad Dermatol. 2004;50:591-594.
10. Werner B, Massone C, Kerl H, et al. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol. 2008;35:1100-1107.
11. Lotze M. CD30. Garland Press and International Workshops on Human Leukocyte Differentiation Antigens; 1999. Available at: httt://www. sciencegateway.org/resources/prow/guide/987522133-g.htm. 1999. Accessed January 13, 2009.
12. Leroy D, Dompmartin A, Michel M, et al. Factors influencing the photoreproduction of hydroa vacciniforme lesions. Photodermatol Photoimmunol Photomed. 1997;13:98-102.
13. Heo EP, Park SH, Kim TH. Artificial reproduction of atypical hydroa vacciniforme caused by latent Epstein-Barr virus infection. Int J Dermatol. 2003;42:476-479.
14. Cho KH, Lee SH, Kim CW, et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol. 2004;151:372-380.
15. Morita A, Werfel T, Stege H, et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med. 1997;186:1763-1768.
16. Hayakawa M, Miyashita H, Sakamoto I, et al. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J. 2003;22: 3356-3366.
17. Prince S, Keating S, Fielding C, et al. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol. 2003;77:5000-5007.
18. Liu SF, Wang H, Lin XC, et al. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. Cell Biol Int. 2008;32:1006-1013.
19. Carlson JA, Perlmutter A, Tobin E, et al. Adverse antibiotic-induced eruptions associated with Epstein Barr virus infection and showing Kikuchi-Fujimoto disease-like histology. Am J Dermatopathol. 2006;28: 48-55.
20. Lim WH, Kireta S, Russ GR, et al. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice. Blood. 2007;109:1043-1050.
21. Hishizawa M, Imada K, Kitawaki T, et al. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br J Haematol. 2004;125:568-575.
22. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237-249.
23. Chaturvedi V, Bodner B, Qin JZ, et al. Knock down of p53 levels in human keratinocytes increases susceptibility to type I and type II interferon-induced apoptosis mediated by a TRAIL dependent pathway. J Dermatol Sci. 2006;41:31-41.
24. Sayama K, Yonehara S, Watanabe Y, et al. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol. 1994;103:330-334.
25. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27:504-528.
26. Rosina P, Girolomoni G. Cutaneous necrosis complicating the injection of pegylated interferon-2b in a patient with chronic hepatitis C. Acta Dermatovenerol Croat. 2008;16:35-37.
27. Ozden MG, Erel A, Erdem O, et al. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient. J Eur Acad Dermatol Venereol. 2005;19:112-113.
28. Krainick U, Kantarjian H, Broussard S, et al. Local cutaneous necrotizing lesions associated with interferon injections. J Interferon Cytokine Res. 1998;18:823-827.
29. Sasseville D, Ghamdi WA, Khenaizan SA. Interferon-induced cutaneous necrosis. J Cutan Med Surg. 1999;3:320-323.
30. Charron A, Bessis D, Dereure O, et al. [Local cutaneous side effects of interferons]. Presse Med. 2001;30:1555-1560.
31. Goldgeier MH, Nordlund JJ, Lucky AW, et al. Hydroa vacciniforme: diagnosis and therapy. Arch Dermatol. 1982;118:588-591.
32. Ketterer R, Morier P, Frenk E. Hydroa vacciniforme. Dermatology. 1994; 189:428-429.
33. Wierzbicka E, Malthieu F, Villers A, et al. Oral involvement in hydroa vacciniforme. Arch Dermatol. 2006;142:651.
34. Bickers DR, Demar LK, DeLeo V, et al. Hydroa vacciniforme. Arch Dermatol. 1978;114:1193-1196.
35. Schiff M, Jillson OF. Photoskin tests in hydroa vacciniforme. Arch Dermatol. 1960;82:812-816.
36. Sonnex TS, Hawk JL. Hydroa vacciniforme: a review of ten cases. Br J Dermatol. 1988;118:101-108.
37. Yasuda H, Leelahavanichkul A, Tsunoda S, et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol. 2008;294:F1050-F1058.
38. Kang SS, Kauls LS, Gaspari AA. Toll-like receptors: applications to dermatologic disease. J Am Acad Dermatol. 2006;54:951-983; quiz 83-86.
39. Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med. 2005;202:817-828.
40. Zinkernagel RM, Hengartner H. On immunity against infections and vaccines: credo 2004. Scand J Immunol. 2004;60:9-13.
41. Blackwell V, McGregor JM, Hawk JL. Hydroa vacciniforme presenting in an adult successfully treated with cyclosporin A. Clin Exp Dermatol. 1998;23:73-76.
42. Naranjo-Gomez M, Climent N, Cos J, et al. Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion. Immunology. 2006;119:488-498.
43. Boor PP, Metselaar HJ, Mancham S, et al. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant. 2006;6:2332-2341.
44. Carrillo-Infante C, Abbadessa G, Bagella L, et al. Viral infections as a cause of cancer (review). Int J Oncol. 2007;30:1521-1528.